Lyell Immunopharma (NASDAQ:LYEL) Trading Up 5.9%

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s share price was up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.17 and last traded at $2.16. Approximately 158,847 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 985,758 shares. The stock had previously closed at $2.04.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The business’s 50 day simple moving average is $2.15 and its two-hundred day simple moving average is $1.93.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. On average, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in shares of Lyell Immunopharma by 6.0% during the second quarter. BlackRock Inc. now owns 13,081,793 shares of the company’s stock valued at $41,600,000 after purchasing an additional 744,660 shares during the period. Vanguard Group Inc. increased its holdings in shares of Lyell Immunopharma by 16.7% during the third quarter. Vanguard Group Inc. now owns 12,406,613 shares of the company’s stock valued at $90,940,000 after acquiring an additional 1,776,617 shares in the last quarter. WuXi AppTec Co. Ltd. acquired a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $15,871,000. State Street Corp increased its holdings in shares of Lyell Immunopharma by 107.2% during the third quarter. State Street Corp now owns 5,379,838 shares of the company’s stock valued at $39,434,000 after acquiring an additional 2,783,919 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Lyell Immunopharma by 7.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,967,338 shares of the company’s stock worth $9,364,000 after buying an additional 291,652 shares during the period. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.